49 completed, 6 recruiting, 6 terminated, 1 available. 36 Phase 1, 19 Phase 3, 13 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 36 | Completed 29, Terminated 4, Recruiting 3 |
| Phase 3 | 19 | Completed 16, Recruiting 2, Terminated 1 |
| Phase 2 | 13 | Completed 10, Terminated 2, Withdrawn 1 |
Follow Basilea Pharmaceutica: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Multiple-dose Study Investigating the Drug-drug Interaction Potential and QTc Effects of Fosmanogepix in Healthy Adult Subjects Fosmanogepix, Placebo, The medicine cocktail (caffeine, bupropion, flurbiprofen, omeprazole, dextromethorphan and midazolam) - Healthy Adult Participants | Phase 1 | Recruiting | Basilea Pharmaceutica | 42 | 2026-10-01 | 2026-10-19 |
| A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BAL2420 in Healthy Adult Subjects BAL2420 or placebo - Healthy | Phase 1 | Recruiting | Basilea Pharmaceutica | 136 | 2026-03-04 | 2026-09-14 |
| A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections. Fosmanogepix IV infusion, Standard of care antifungal therapy, Fosmanogepix oral tablet - Invasive Mold Infections | Phase 3 | Recruiting | Basilea Pharmaceutica | 234 | 2025-08-26 | 2026-09-14 |
| A Study of Fosmanogepix in Healthy Adult Chinese Subjects Oral Fosmanogepix, IV Fosmanogepix, IV placebo - Healthy | Phase 1 | Completed | Basilea Pharmaceutica | 54 | 2025-04-14 | 2026-04-06 |
| A Study to Assess the Effect of Ceftobiprole on the PK of Pitavastatin and on Plasma Levels of Coproporphyrin pitavastatin, pitavastatin single dose combined with ceftobiprole - Drug-drug Interaction Study | Phase 1 | Completed | Basilea Pharmaceutica | 12 | 2025-01-17 | 2026-04-21 |
| Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination Ledaborbactam etzadroxil, Ceftibuten, Ceftibuten-ledaborbactam etzadroxil - Healthy Volunteer, Pharmacokinetics | Phase 1 | Recruiting | Basilea Pharmaceutica | 96 | 2025-01-07 | 2026-07-09 |
| A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis. Fosmanogepix, Caspofungin, Fluconazole - Candidemia, Candidiasis, Invasive | Phase 3 | Recruiting | Basilea Pharmaceutica | 450 | 2024-12-11 | 2026-10-19 |
| Plasma and Intrapulmonary Pharmacokinetics of Ceftibuten and Ledaborbactam in Healthy Adults (18-55 Years) ledaborbactam etzadroxil, ceftibuten - Pharmacokinetics, Healthy Volunteers | Phase 1 | Completed | Basilea Pharmaceutica | 34 | 2024-11-04 | 2026-08-24 |
| Late-onset Sepsis in Term and Pre-term Neonates and Infants up to 3 Months of Age Ceftobiprole medocaril - Neonatal Sepsis | Phase 3 | Completed | Basilea Pharmaceutica | 9 | 2023-08-06 | 2025-07-28 |
| A Clinical Trial of the Study Medicine (Called Fosmanogepix) in Participants With Varying Degrees of Hepatic Function. Fosmanogepix - Hepatic Impairment | Phase 1 | Completed | Basilea Pharmaceutica | 28 | 2022-10-31 | 2025-12-19 |
| Ceftibuten/VNRX-7145 in Participants With Varying Degrees of Renal Function VNRX-7145, Ceftibuten - Pharmacokinetics | Phase 1 | Completed | Basilea Pharmaceutica | 32 | 2022-10-12 | 2025-12-08 |
| Food Effect on Ceftibuten/VNRX-7145 in Healthy Participants VNRX-7145, Ceftibuten - Pharmacokinetics | Phase 1 | Completed | Basilea Pharmaceutica | 24 | 2022-09-13 | 2025-12-08 |
| VNRX-7145 Drug-Drug Interaction in Healthy Adult Volunteers VNRX-7145, VNRX-5024 (ceftibuten), Placebo - Healthy Subjects | Phase 1 | Completed | Basilea Pharmaceutica | 53 | 2021-06-08 | 2025-12-08 |
| A Bioequivalence Study of APX001 High-load and Low-load Tablets APX001, APX001A - Invasive Fungal Infections | Phase 1 | Completed | Basilea Pharmaceutica | 18 | 2021-03-02 | 2024-07-11 |
| Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma Derazantinib, Derazantinib-paclitaxel-ramucirumab combination - Gastric Adenocarcinoma | Phase 1 / Phase 2 | Terminated | Basilea Pharmaceutica | 47 | 2020-10-06 | 2024-04-04 |
| VNRX-5024 Safety and PK in Healthy Adult Volunteers VNRX-5024, Placebo for VNRX-5024 - Healthy Subjects | Phase 1 | Completed | Basilea Pharmaceutica | 36 | 2020-07-27 | 2025-12-03 |
| VNRX-7145 SAD/MAD Safety and PK in Healthy Adult Volunteers VNRX-7145, Placebo - Healthy Volunteers | Phase 1 | Completed | Basilea Pharmaceutica | 83 | 2020-01-20 | 2025-12-03 |
| Open-label Study of APX001 for Treatment of Patients With Invasive Mold Infections Caused by Aspergillus or Rare Molds fosmanogepix - Invasive Fungal Infections | Phase 2 | Terminated | Basilea Pharmaceutica | 21 | 2020-01-04 | 2025-09-16 |
| An Open-label Study of APX001 for Treatment of Patients With Candidemia/Invasive Candidiasis Caused by Candida Auris APX001 - Candidemia, Invasive Candidiases | Phase 2 | Completed | Basilea Pharmaceutica | 9 | 2019-12-13 | 2025-09-16 |
| A Drug-Drug Interaction Study of CYP3A4 Inhibition and Pan-CYP Induction on APX001 APX001, Itraconazole, Rifampin - Fungal Infection | Phase 1 | Completed | Basilea Pharmaceutica | 36 | 2019-11-12 | 2024-05-17 |
Showing 20 of 64. Sign in to see all of them.
Mycoses (9) · Staphylococcal Skin Infections (6) · Candidemia (4) · Invasive Fungal Infections (4) · Streptococcal Infections (4) · Biliary Tract Neoplasms (3) · Candidiasis, Invasive (3) · Cholangiocarcinoma (3) · Hand Dermatoses (3) · Liver Neoplasms (3) · Neoplasms (3) · Pneumonia (3) · Pneumonia, Ventilator-Associated (3) · Torulopsis (3) · Acrocephalosyndactylia (2)
ceftobiprole (13) · ceftobiprole medocaril (10) · Alitretinoin (6) · derazantinib (6) · Ceftibuten (5) · lisavanbulin (4) · Ceftazidime (3) · Linezolid (3) · Vancomycin (3) · isavuconazole (3) · Caspofungin (2) · Midazolam (2) · APX001A (1) · Amoxicillin-Potassium Clavulanate Combination (1) · Bupropion (1)
United States (24) · Germany (20) · Belgium (10) · Netherlands (10) · Spain (9) · France (8) · Italy (8) · United Kingdom (8) · Israel (7) · Canada (6) · Australia (5) · Bulgaria (5) · Poland (5) · South Korea (5) · Switzerland (5)
Marc Engelhardt (9) · Marc Engelhardt, MD (7) · Kamal Hamed, MD (6) · Thomas Kaindl, MD (5) · Thomas Ruzicka, MD (2) · Alexandra Hill, MD (1) · Alison Kuchta, MD (1) · Kamal Hamed, MD, MPH (1)
PMID 33960817, PMID 30808293, PMID 34155899, PMID 24723282, PMID 30420614, PMID 34533489, PMID 36988461, PMID 40762486, PMID 41251370, PMID 18225981, PMID 19659963, PMID 20926263, PMID 22230331, PMID 25607554, PMID 25624327, PMID 25902926, PMID 26969258, PMID 27627808, PMID 27846057, PMID 28972963, PMID 30289478, PMID 31471863, PMID 32897367, PMID 33480665, PMID 35144992, PMID 36792805, PMID 37022196, PMID 37596890, PMID 37754204, PMID 38627238, PMID 38757982, PMID 39012090, PMID 40203286, PMID 40532659, PMID 40762485, PMID 42008649, PMID 42774582, PMID 42803753
272201600029C-P00007-9999-2 (3), 2019 (2), 2005 (1), 2025 (1), 272201600029C-P00017-9999-1 (1), 272201600029C-P00026-9999-1 (1)